18 results about "Mitomycin C" patented technology

The present invention belongs to the field of insect cell culture technology and discloses a method for preparing an Sf9 cell feeder layer. The method mainly comprises two steps: step S1 is subculture of Sf9 cells, in which Sf9 cells are cultured in a suitable culture medium to a suitable cell confluence; step S2 is mitomycin C treatment of the Sf9 cells, in which a specific concentration of mitomycin C is used to treat the subcultured Sf9 cells at a specific time and temperature to inhibit their cell division ability, followed by washing to remove mitomycin C and replacing with fresh culture medium. The feeder layer cells obtained by the present invention can effectively inhibit their own proliferation while maintaining good cell activity and structural integrity. They can survive stably and provide necessary support for the co-culture system. They can be used for the cultivation of insect symbiotic bacteria and other difficult-to-culture insect cells. The method is simple to operate, has mild conditions, and good reproducibility. The prepared feeder layer has a stable effect, providing a powerful tool for related research fields.

A lysogenic phage community, its extraction method and application. The tangential flow technology is used to proportionally isolate bacteria and phage communities from in-situ soil, and single-bacteria communities and single-phage communities are obtained through enrichment and concentration. At the same time, mitomycin C is added to the single-bacteria community for lysogenic induction, and then the tangential flow system is used again for filtration and enrichment to obtain a high-throughput lysogenic phage community. Finally, we obtain single-bacteria communities, bacteria-phage mixed communities, and bacteria-lysogenic phage mixed communities. The phage transplantation technology can promote the participation of indigenous microorganisms in the process of promoting plant growth and development. The transplanted lysogenic phages can participate in the synthesis and metabolism of host plant hormones by optimizing the microbial network structure and injecting auxiliary metabolic genes. This method provides a long-term and environmentally friendly microbial synergistic growth promotion technology for the development of green agriculture in China.

The invention provides a method for purifying mitomycin C. The method comprises the following steps: step 1, adding a surfactant or / and guanidine hydrochloride into fermentation liquor, and carrying out solid-liquid separation; 2, separating through a chromatographic column to obtain a solution containing mitomycin C; and step 3, obtaining a mitomycin C solid from the mitomycin C solution. According to the method provided by the invention, high-purity mitomycin C can be obtained, the yield is high, and the method is suitable for large-scale industrial production.

The invention discloses a preparation method of feeder layer cells and application of the feeder layer cells in primary tumor cell culture, and belongs to the technical field of biology. The method comprises the following steps: digesting tumor tissues by using collagenase and hyaluronidase, resuspending cells by using a culture medium, passing through a cell sieve, inoculating into a culture vessel for culture, obtaining tumor-related fibroblasts through differential digestion, repeating the steps of culture and differential digestion, adding the obtained fibroblasts into a culture medium containing 25-35mu g / ml mitomycin C, and treating for 3-5 hours, thereby obtaining the tumor-related fibroblasts. And cleaning the cells with a fresh culture medium for 1-5 times to obtain the feeder layer cells. The operation process is simple, compared with general trophoblast cells 3T3-J2 (Kerafast company), the trophoblast cells 3T3-J2 are low in price and easy to obtain, the problem that the culture period is limited is solved, the prepared feeder layer cells can be directly applied to primary tumor cell culture, and the cost of primary tumor cell culture is further reduced.

The invention belongs to the field of molecular biology, and particularly relates to a construction method and application of phosphorylation mutation sites of phosphoglucomutase. The mutation site is obtained by mutating threonine at the 144th site of escherichia coli wild-type phosphoglucomutase into aspartic acid, the sensitivity of an escherichia coli mutant strain with the mutation site to nalidixic acid, mitomycin C and tetracycline is remarkably improved, and the mutation site can be used for improving the sensitivity of bacteria to drugs.

The invention discloses a mitomycin C drug sensitive marker, a detection reagent and application of the mitomycin C drug sensitive marker, the mitomycin C drug sensitive marker is a mitomycin C drug-resistant marker or / and a mitomycin C sensitive marker, and the mitomycin C drug-resistant marker is one or more of PRODH, ANKRD35, ADAMTSL5, PTPRQ, NOXA1, PRAC1, CRYM, NFIB, SYK or DGAT2; and the mitomycin C sensitive marker is one or more of GABRP (gamma-aminobutyric acid binding protein), PABPC1L (poly (p-aminobutyric acid binding protein 1L) or PODXL2 (peroxidase The mitomycin C drug sensitive marker can be used for predicting the drug effect of mitomycin C. According to the present invention, the expression of the related molecules is detected by sequencing the transcriptome of the tissue of the urothelium carcinoma patient, or by using the PC R, the gene chip, the tissue chip, the NanoString technology, the immunohistochemistry and the ELISA method, such that the clue can be provided for the medication of the mitomycin C and the precise treatment of the bladder cancer.

This invention relates to the use of small molecule compounds that allosterically inhibit ALC1 (CHD1L), particularly two classes of ALC1 (CHD1L) allosteric inhibitors of formulas (I) and (II). When combined with inhibitors of several classes of cancer drugs, namely topoisomerase I, topoisomerase II, ATM, ATR, Wee1, BRD, and MEK, or when combined with mitomycin C, paclitaxel, ionizing radiation, or antibody-drug conjugates having tumor-specific antibodies conjugated to TOP1 inhibitors, the small molecule compounds and the allosteric inhibitors exhibit enhancing, preferably additive, effects in the treatment of proliferative diseases. Furthermore, this invention relates to the ALC1 inhibitor of formula (II), which, when combined with PARP inhibitors (poly(ADP-ribose)-polymerase inhibitors (PARPi)), exhibit synergistic effects in the treatment of pancreatic cancer or fallopian tube cancer. By synergizing with the functions of the aforementioned cancer drugs, the ALC1 inhibitors, particularly those of formulas (I) and (II) that enhance the cancer cell killing properties of the aforementioned cancer drugs, are particularly capable of achieving treatments in which any of the aforementioned inhibitors have already been used as part of standard care.

The invention belongs to the field of molecular biology, and particularly relates to a construction method and application of a phosphoenolpyruvate synthase T419D mutation site. The mutation site is obtained by mutating threonine at the 419th site of phosphoenolpyruvate synthase of an escherichia coli wild type into aspartic acid, the sensitivity of an escherichia coli mutant strain with the mutation site to nalidixic acid, mitomycin C and polymyxin sulfate B is remarkably improved, and the mutation site can be used for improving the sensitivity of bacteria to drugs.

The invention relates to the technical field of nano materials, in particular to catechol derivative ligands, gold nanoparticles modified by the catechol derivative ligands and application of the catechol derivative ligands. The catechol derivative modified gold nanoparticles provided by the invention can be used as a biological reducing agent, specifically, the specific value of GSH / GSSG in tumor cells is increased, the specific value of NADPH / NADP + is increased, the content of extracellular H2O2 is reduced, the content of GPx is increased, the content of MDA is reduced, and a reductive stress state is formed, so that the catechol derivative modified gold nanoparticles can be used as the biological reducing agent. In a reductive stress state, not only can the proliferation rate of tumor cells be inhibited, but also the mitomycin C can be activated, and the treatment effect of the mitomycin C on tumors can be improved.

The application discloses a molecular imprinting ratio type working electrode for detecting mitomycin C and a preparation method and application thereof, and belongs to the technical field of analysis and detection. The application aims to solve the problem of simple and accurate detection of the content of mitomycin C (MMC). The application adopts a solvothermal reaction to prepare cerium-nickel bimetallic organic framework material, adopts ultrasonic reaction to prepare cerium-nickel bimetallic organic framework / multi-walled carbon nanotube composite material, and adopts the cerium-nickel bimetallic organic framework / multi-walled carbon nanotube composite material and thionine as a modification material of an electrochemical sensing interface. A molecular imprinting ratio type electrochemical sensor with specific recognition response to a template molecule MMC is prepared on the surface of the modified electrode through an electrochemical polymerization method. The application is applied to the detection of the content of MMC, and has the advantages of simple operation, low cost, high sensitivity and good selectivity.

The invention discloses a molecularly imprinted ratio-type working electrode for detecting mitomycin C as well as a preparation method and application of the molecularly imprinted ratio-type working electrode, and belongs to the technical field of analysis and detection. The invention aims to solve the problem that the content of mitomycin C (MMC) can be simply, conveniently and accurately detected. According to the preparation method, a cerium-nickel bimetal organic framework material is prepared through solvothermal reaction, a cerium-nickel bimetal organic framework / multi-walled carbon nanotube composite material is prepared through ultrasonic reaction, and the cerium-nickel bimetal organic framework / multi-walled carbon nanotube composite material and thionine are used as modification materials of an electrochemical sensing interface. And preparing the molecular imprinting ratio type electrochemical sensor with specific recognition response to the template molecule MMC on the surface of the modified electrode through an electrochemical polymerization method. The method is applied to MMC content detection, and has the advantages of simple operation, low cost, high sensitivity and good selectivity.

This invention relates to the field of nanomaterials technology, specifically to a catechol derivative ligand and its modified gold nanoparticles and their applications. The catechol derivative-modified gold nanoparticles provided by this invention can act as bioreducing agents, specifically by increasing the GSH / GSSG ratio and NADPH / NADP ratio in tumor cells. + By adjusting the ratio, reducing extracellular H2O2 content, increasing GPx content, and decreasing MDA content, a reducing stress state is formed, thus enabling it to act as a biological reducing agent. Under reducing stress, it can not only inhibit the proliferation rate of tumor cells but also activate mitomycin C, enhancing the therapeutic effect of mitomycin C on tumors.

The invention belongs to the technical field of insect cell culture, and discloses a preparation method of an Sf9 cell feeder layer, which mainly comprises the following two steps: S1, subculturing Sf9 cells: culturing the Sf9 cells in a suitable culture medium to a suitable cell confluence degree; and S2, mitomycin C treatment of the Sf9 cells: treating the subcultured Sf9 cells at specific time and temperature by using mitomycin C with specific concentration to inhibit the cell division ability of the Sf9 cells, then washing to remove the mitomycin C, and replacing a fresh culture medium. The obtained feeder layer cells can effectively inhibit self proliferation, maintain good cell activity and structural integrity, can stably survive and provide necessary support for a co-culture system, and can be used for culture of insect symbiotic bacteria and other insect cells difficult to culture; the method is easy and convenient to operate, mild in condition and good in repeatability, the prepared feeding layer is stable in effect, and a powerful tool is provided for the related research field.

The invention belongs to the technical field of cancer treatment, and particularly relates to a tumor targeted activated mitomycin C compound. The structural formula of the tumor targeted activated mitomycin C compound is shown as the following formula: E-(PEG) x-L1-L2-L3-L4-D. The invention further discloses a preparation method of the tumor targeted activated mitomycin C compound. The tumor targeted activated mitomycin C compound has the beneficial effects that the tumor targeted activated mitomycin C compound has relatively good water solubility and relatively strong tumor targeting property, after the tumor targeted activated mitomycin C compound is used, the tumor targeted activated mitomycin C compound can release mitomycin C when reaching a tumor part, so that the tumor targeted activated mitomycin C compound has a good tumor targeting effect, and the tumor targeted activated mitomycin C compound can be applied to tumor treatment. Therefore, tumor cells are killed. Meanwhile, the compound is less released in normal tissues and blood and has slight toxic and side effects on the normal tissues, so that the purposes of targeting tumor tissues and reducing toxic and side effects can be achieved.

The invention provides a method for inducing a lyogenic phage based on xanthohumol and application thereof, which are suitable for inducing the lyogenic phage in an escherichia coli host and show a remarkable induction effect. Compared with induction by using 1.5 mu g / ml mitomycin C, the fulvic acid with the final concentration of 1 mu g / ml can induce higher bacteriophage titer; in an in-vivo experiment, a mouse infected with escherichia coli is treated by orally taking xanthohumol, the bacterial load can be remarkably reduced, the phage titer is improved, no obvious toxicity exists, a CCK-8 experiment shows that the survival rate of HepG2 cells given with xanthohumol is remarkably higher than that of HepG2 cells given with mitomycin C group with the same concentration, and xanthohumol shows lower cytotoxicity. The method for inducing the lysogenic bacteriophage based on the xanthohumol is suitable for the fields of bacteriophage therapy, microbiology, microbial ecology and the like, and has a wide application prospect.

The present invention relates to the field of pharmaceutical technology, and particularly to a mitomycin lyophilized powder, a low-temperature drying device and method for use after pterygium surgery. The lyophilized powder is prepared from a pre-freeze-drying solution through a freeze-drying process; in the pre-freeze-drying solution by mass, it includes mitomycin C: 0.75 mg / ml - 0.95 mg / ml, mannitol: 1.6 mg / ml - 2 mg / ml, and water for injection: make up to the volume. The mitomycin pre-freeze-drying solution provided by the present invention strictly controls the proportion of the solvent system, improves the solution stability, reduces the reconstitution time, reduces the probability of product solvent residue, has better stability of the finished product, and reduces the safety risk of the product.

The present invention relates to compounds comprising a glycopeptide antibiotic, such as vancomycin, dalbavancin or teicoplanin, or a mitomycin C, one or more antibacterial agents, and a biodegradable linker linking the glycopeptide antibiotic, such as vancomycin, dalbavancin or teicoplanin, or the mitomycin C and the one or more antibacterial agents.

A kit provides for sustained release of therapeutic agents for local treatment of cancer diseases by providing lyophilized Mitomycin C in a slowly releasing biocompatible hydrogel to be applied to affected tissue. The hydrogel comprises poloxamer 407, hydroxypropylmethylcellulose and water. A lyophilized composition comprises mitomycin C and urea as a bulking agent.